Претраживање
Приказ резултата 1-10 од 91
Serologic rebounds after one-year-long treatment for congenital toxoplasmosis
(Lippincott Williams & Wilkins, Philadelphia, 2000)
EURRECA-Estimating Selenium Requirements for Deriving Dietary Reference Values
(Taylor & Francis Inc, Philadelphia, 2013)
Current reference values for selenium, an essential micronutrient, are based on the intake of selenium that is required to achieve maximal glutathione peroxidase activity in plasma or erythrocytes. In order to assess the ...
Expression analysis of jak-stat dependent s100 calcium binding proteins a4 and a12 in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2013)
Globin genes induction by nitric oxide of stromal cell origin
(Amer Soc Hematology, Washington, 2007)
Haemodynamic effects of no and vitamin C supplementation in SHR with acute renal failure
(Lippincott Williams & Wilkins, Philadelphia, 2006)
Developmental and differential changes of gene expression in erythroid progenitor cells.
(Amer Soc Hematology, Washington, 2005)
Combined endothelin and AII blockade reduces mean arterial pressure and fails to improve postischaemic acute renal failure
(Lippincott Williams & Wilkins, Philadelphia, 2003)
EURRECA-Estimating Iodine Requirements for Deriving Dietary Reference Values
(Taylor & Francis Inc, Philadelphia, 2013)
Iodine is an essential component of thyroid hormones, and current recommendations for intake are based on urinary iodine excretion, assessment of thyroid size, thyroidal iodine accumulation and turnover, radioactive iodine ...
Influence of microenvironmental conditions on hybridoma cell growth inside the alginate-poly-L-lysine microcapsule
(Elsevier Sci Ltd, Oxford, 2007)
A mathematical model was formulated to describe hybridoma cell growth within the alginate-poly-L-lysine (alginate-PLL) microcapsules during air-lift bioreactor cultivation. Model development was based on experimentally ...
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
(Amer Soc Hematology, Washington, 2008)
Hydroxyurea, a drug widely used for treating myeloproliferative diseases, has also been approved for the treatment of sickle cell disease by raising fetal hemoglobin (HbF). We have shown that nitric oxide (NO) and the ...